文献速递头颈部肿瘤放疗放疗物理与技术

头颈部每日自适应放疗近无边缘策略的计算机模拟评估与可行性

In silico evaluation and feasibility of near margin-less head and neck daily adaptive radiotherapy.
PubMed 文献 · Radiother Oncol · 2024-03-06

本研究基于II期试验中10例头颈癌患者,利用Ethos系统/智能优化引擎模拟每日自适应放疗,比较1 mm与5 mm计划靶区外扩及体积缩减的剂量学影响。结果显示自适应计划改善了70 Gy、66.5 Gy和63 Gy的PTV V100%覆盖,并使下颌下腺、腮腺、口腔和咽缩肌等关键危及器官中位剂量降低7-12 Gy。作者结论为IOE使每日自适应放疗在缩减边缘下可行,同时改善靶区覆盖并降低危及器官剂量。

要点

  • 每日自适应放疗在1 mm外扩下改善PTV覆盖,70 Gy、66.5 Gy和63 Gy的V100%中位数分别为96% vs 95.6%、98.5% vs 76.5%、98.9% vs 74.9%(p<0.03)。
  • 体积缩减的自适应放疗使下颌下腺、腮腺、口腔和咽缩肌等关键危及器官中位剂量降低7-12 Gy(p<0.05)。
  • 原发和淋巴结大体肿瘤体积所需调整最多,中位Dice评分分别为0.88和0.83。

核心结论

  • IOE使头颈癌患者每日自适应放疗在缩减边缘下可行,同时改善靶区覆盖并降低危及器官剂量。
  • 一项II期试验近期完成入组,即将进行的分析将确定这些剂量学改善是否与患者报告结局改善相关。

研究设计与样本

  • 从一项II期试验中选取10例头颈癌患者,将其锥形束CT扫描上传至自适应放疗模拟器。
  • 使用1 mm和5 mm计划靶区外扩生成新的初始参考计划,并从每第五分次的临床锥形束CT模拟每日自适应放疗计划(1 mm)。
  • 使用医师修改的自适应放疗轮廓,在每日解剖上重新计算较大的5 mm计划,并以Dice系数衡量靶区和危及器官轮廓变化。
  • 比较PTV覆盖和危及器官剂量,并在第5和第35分次评估每个自适应放疗计划的稳健性,观察危及器官剂量是否在预计划3 Gy以内。

主要发现

  • 研究纳入6例口咽癌和4例喉癌患者,共70个自适应分次。
  • 原发和淋巴结大体肿瘤体积所需调整最多,中位Dice评分分别为0.88(范围0.80-0.93)和0.83(范围0.66-0.91)。
  • 第5和第35分次计划中,80%的结构满足稳健性标准(四分位1-3:67-100%和70-90%)。
  • 自适应计划改善70 Gy、66.5 Gy和63 Gy的中位PTV V100%覆盖:96% vs 95.6%、98.5% vs 76.5%、98.9% vs 74.9%(p<0.03)。
  • 实施体积缩减的自适应放疗使下颌下腺、腮腺、口腔和咽缩肌等关键危及器官中位剂量降低7-12 Gy(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We explore the potential dosimetric benefits of reducing treatment volumes through daily adaptive radiation therapy for head and neck cancer (HNC) patients using the Ethos system/Intelligent Optimizer Engine (IOE). We hypothesize reducing treatment volumes afforded by daily adaption will significantly reduce the dose to adjacent organs at risk. We also explore the capability of the Ethos IOE to accommodate this highly conformal approach in HNC radiation therapy. METHODS: Ten HNC patients from a phase II trial were chosen, and their cone-beam CT (CBCT) scans were uploaded to the adaptive RT (ART) emulator. A new initial reference plan was generated using both a 1 mm and 5 mm planning target volume (PTV) expansion. Daily adaptive ART plans (1 mm) were simulated from the clinical CBCT taken every fifth fraction. Additionally, using physician-modified ART contours the larger 5 mm plan was recalculated on this recontoured on daily anatomy. Changes in target and OAR contours were measured using Dice coefficients as a surrogate of clinician effort. PTV coverage and organ-at-risk (OAR) doses were statistically compared, and the robustness of each ART plan was evaluated at fractions 5 and 35 to observe if OAR doses were within 3 Gy of pre-plan. RESULTS: This study involved six patients with oropharynx and four with larynx cancer, totaling 70 adaptive fractions. The primary and nodal gross tumor volumes (GTV) required the most adjustments, with median Dice scores of 0.88 (range: 0.80-0.93) and 0.83 (range: 0.66-0.91), respectively. For the 5th and 35th fraction plans, 80 % of structures met robustness criteria (quartile 1-3: 67-100 % and 70-90 %). Adaptive planning improved median PTV V100% coverage for doses of 70 Gy (96 % vs. 95.6 %), 66.5 Gy (98.5 % vs. 76.5 %), and 63 Gy (98.9 % vs. 74.9 %) (p < 0.03). Implementing ART with total volume reduction yielded median dose reductions of 7-12 Gy to key organs-at-risk (OARs) like submandibular glands, parotids, oral cavity, and constrictors (p < 0.05). CONCLUSIONS: The IOE enables feasible daily ART treatments with reduced margins while enhancing target coverage and reducing OAR doses for HNC patients. A phase II trial recently finished accrual and forthcoming analysis will determine if these dosimetric improvements correlate with improved patient-reported outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Dohopolski M, Visak J, Choi B, et al. In silico evaluation and feasibility of near margin-less head and neck daily adaptive radiotherapy. Radiother Oncol. 2024. PMID: 38453056. doi:10.1016/j.radonc.2024.110178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。